Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax , mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Show more

325 Binney Street, Cambridge, MA, 02142, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

19.65B

52 Wk Range

$22.28 - $55.20

Previous Close

$50.29

Open

$50.18

Volume

7,001,503

Day Range

$49.54 - $51.97

Enterprise Value

7.753B

Cash

4.504B

Avg Qtr Burn

-847M

Insider Ownership

7.39%

Institutional Own.

77.46%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

mRESVIA (mRNA-1345) Details
Respiratory syncytial virus

Approved

Quarterly sales

Approved

Quarterly sales

PDUFA

Approval decision

mRNA-1083 Details
COVID-19, Influenza

BLA

Resubmission

mRNA-3927 Details
Propionic acidemia

Phase 3

Data readout

mRNA-4157/V940 +KEYTRUDA Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

mRNA-1403 Details
Norovirus vaccine

Phase 3

Data readout

Phase 3

Update

mRNA-3705 Details
Rare diseases, Methylmalonic acidemia

Phase 3

Initiation

Phase 2

Data readout

Intismeran Autogene (mRNA-4157/V940) (Neoantigen Vaccine) Details
High-Risk Muscle-Invasive And Non-Muscle-Invasive Bladder Cancer

Phase 2

Initiation

mRNA-2808 Details
Multiple Myeloma

Phase 1/2

Data readout

mRNA-1468 Details
Varicella-zoster virus

Phase 1/2

Data readout

mRNA-1018 Details
H5N1 avian influenza

Phase 1/2

Update

mRNA-1574 Details
Human immunodeficiency virus

Phase 1

Data readout

mRNA-4359 + pembrolizumab Details
Checkpoint Inhibitor-Resistant/Refractory (CPI-R/R) Melanoma

Phase 1

Update

mRNA-1647 Details
Cytomegalovirus

Failed

Discontinued